Pegylated Liposomal Doxorubicin (Caelyx) in Combination With Herceptin [trastuzumab] and Taxotere [docetaxel] as First-Line Chemotherapy in Metastatic Breast Cancer Patients: A 2 Stage Phase II, Open Label, Multicenter Study.

Trial Profile

Pegylated Liposomal Doxorubicin (Caelyx) in Combination With Herceptin [trastuzumab] and Taxotere [docetaxel] as First-Line Chemotherapy in Metastatic Breast Cancer Patients: A 2 Stage Phase II, Open Label, Multicenter Study.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Docetaxel; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Schering-Plough
  • Most Recent Events

    • 17 Feb 2010 Actual patient number (27) added as reported by ClinicalTrials.gov.
    • 17 Dec 2008 Planned end date (Oct 2008) added as reported by ClinicalTrials.gov.
    • 17 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top